

First-quarter Figures:**Sartorius Stedim Biotech off to a dynamic start into 2015**

€ in millions unless otherwise specified Unaudited figures	3 months 2015	3 months 2014	Growth in %	Growth in % const. fx
Order intake	224.1	175.3	27.9	17.1
Sales revenue	204.4	154.0	32.8	21.5
EMEA ¹	97.5	80.2	21.6	19.2
Americas ¹	70.2	44.6	57.4	31.2
Asia Pacific ¹	36.8	29.2	25.9	13.0
EBITDA ²	50.8	33.3	52.4	
EBITDA margin ² in %	24.8	21.6		
Net profit ³	29.6	18.1	64.1	
Earnings per share in € ³	1.93	1.18	64.1	

Sartorius Stedim Biotech S.A.
 Z.I. Les Paluds
 Avenue de Jouques
 C.S. 91051
 13781 Aubagne - France
www.sartorius-stedim.com

Contact:
 Petra Kirchhoff
 Phone +49 (0)551.308.1686

Goettingen, April 20, 2015

¹ According to customers' location; definition of regions slightly changed

² Underlying EBITDA = earnings before interest, taxes, depreciation and amortization, and adjusted for extraordinary items

³ Underlying net profit = net profit after non-controlling interest; adjusted for extraordinary items, amortization and based on a normalized financial result and tax rate

Strong double-digit topline growth

In the first three months of 2015, Sartorius Stedim Biotech, a leading supplier for the biopharmaceutical industry, reported gains in order intake and sales revenue well into the double digits. While the company had expected above-average growth rates for the first quarter due to low prior-year comparables, growth was even stronger than anticipated driven by dynamic performance across the portfolio. Regionally, the Americas again posted the highest expansion rate, partly because of the relatively low level in the first quarter of 2014.

Profits on the rise

Sartorius Stedim Biotech reported an overproportionate increase in earnings, mainly driven by economies of scale and favorable currency effects. Underlying EBITDA jumped 52.4% to 50.8 million euros; the corresponding margin reached 24.8%. Extraordinary expenses totaled 0.4 million euros. Underlying earnings per share were 1.93 euros, up year over year from 1.18 euros.

Strong financial performance

The financial position of the Sartorius Stedim Biotech Group has remained strong and stable as reflected by an equity ratio of 59.2% and a ratio of net debt to underlying EBITDA of 0.5. Net debt at the end of the first quarter was 89.1 million euros.

Outlook for 2015 raised

Based on the strong results of the first three months, management has revised its forecast upwards for the full year of 2015. Sales revenue in constant currencies is now expected to increase approximately 7% to 10% (previous guidance approx. 4% to 7%). The underlying EBITDA margin in constant currencies is projected to reach around 24.5% to 25.0% (previous guidance around 24.0% to 24.5%).

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.

Conference call and webcast

Joachim Kreuzburg, CEO and Chairman of the Board of the Sartorius Stedim Biotech Group, will discuss the results with analysts and investors on Monday, April 20, 2015, at 3:00 p.m. Central European Time (CET), in a teleconference. You may dial into the teleconference starting at 2:50 p.m. CET at the following numbers:

Germany: +49(0)69 2222 10637

France: +33(0)1 76 77 22 38

UK: +44(0)20 3427 1926

USA: +1646 254 3369

The dial-in code is: 7111358

To view the webcast or presentation, log onto: www.sartorius-stedim.com

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge products and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions."

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech has a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,700 people, and in 2014 earned sales revenue of 683.5 million euros.

Contact

Petra Kirchhoff, Vice President of Corporate Communications and Investor Relations

Sartorius Corporate Administration GmbH, 37070 Goettingen, Germany

Phone: +49(0)551.308.1686; Fax: +49(0)551.308.3410

E-mail: petra.kirchhoff@sartorius.com; www.sartorius-stedim.com



Income Statement

	3 months 2015 € in mn	3 months 2014 € in mn
Sales revenue	204.4	154.0
Cost of sales	-101.6	-76.1
Gross profit on sales	102.8	77.9
Selling and distribution costs	-39.3	-35.0
Research and development costs	-10.9	-10.3
General administrative expenses	-10.9	-9.5
Other operating income and expenses	-0.4	1.4
Earnings before interest & taxes (EBIT)	41.3	24.5
Financial income	2.0	0.1
Financial expenses	-15.8	-2.6
Financial result	-13.8	-2.5
Profit before tax	27.5	22.0
Deferred tax income expenses	0.9	0.7
Income tax expenses	-8.9	-7.1
Taxes	-8.0	-6.4
Net profit for the period	19.5	15.6
Attributable to:		
Shareholders of Sartorius Stedim Biotech	18.7	15.6
Non-controlling interest	0.8	0.0
Earnings per share (€)	1.22	1.01
Diluted earnings per share (€)	1.22	1.01


Statement of Financial Position

Assets	March 31, 2015 € in mn	Dec. 31, 2014 € in mn
Non-current assets		
Goodwill	317.0	314.4
Intangible assets	111.8	111.9
Property, plant and equipment	200.7	192.2
Financial assets	1.3	1.2
Deferred tax assets	9.8	10.2
Other assets	1.0	0.7
	641.7	630.6
Current assets		
Inventories	127.0	110.0
Trade receivables	145.7	124.8
Other financial assets	8.1	6.8
Current tax assets	14.7	8.9
Other assets	8.9	7.1
Cash and cash equivalents	24.9	18.5
	329.4	276.2
Total assets	971.1	906.8
Equity and liabilities		
	March 31, 2015 € in mn	Dec. 31, 2014 € in mn
Equity		
Attributable to SSB shareholders	566.9	532.5
Issued capital	15.4	15.4
Capital reserves	235.1	235.0
Retained earnings (including net profit)	316.4	282.1
Non-controlling interest	7.6	6.0
	574.5	538.5
Non-current liabilities		
Pension provisions	31.2	30.6
Other provisions	2.9	2.9
Loans and borrowings	14.8	15.9
Finance lease liabilities	17.0	16.8
Other financial liabilities	58.2	44.7
Deferred tax liabilities	24.2	27.8
	148.4	138.7
Current liabilities		
Provisions	6.7	6.2
Trade payables	85.3	81.1
Loans and borrowings	80.6	71.8
Finance lease liabilities	1.6	1.6
Other financial liabilities	46.9	48.1
Current tax liabilities	10.9	10.1
Other liabilities	16.3	10.7
	248.3	229.6
Total equity and liabilities	971.1	906.8



Statement of Cash Flows

	3 months 2015 € in mn	3 months 2014 € in mn
Cash flows from operating activities		
Profit before tax	27.5	22.0
Financial Result	13.8	2.5
Earnings before interest & taxes (EBIT)	41.3	24.5
Depreciation amortization of intangible and tangible assets	9.0	8.1
Increase decrease in provisions	0.4	-0.8
Income taxes paid	-11.7	-5.1
Other non-cash items	-1.6	0.0
Gross cash flows from operating activities	37.4	26.8
Increase decrease in receivables and other assets	-21.7	-2.1
Increase decrease in inventories	-12.0	-7.0
Increase decrease in liabilities	12.2	-3.8
Net cash flow from operating activities	15.9	13.9
Cash flows from investing activities		
Capital expenditure	-10.7	-11.3
Proceeds from the disposal of fixed assets	0.2	0.1
Other payments	0.0	-0.1
Net cash flow from investing activities	-10.6	-11.3
Payments for acquisitions of consolidated subsidiaries and other business operations; net of cash acquired	0.0	0.0
Proceeds from the disposal of consolidated subsidiaries and other business operations	0.0	0.0
Net cash flow from investing activities and acquisitions	-10.6	-11.3
Cash flows from financing activities		
Changes in capital	0.1	0.0
Interest received	0.0	0.1
Interest paid and other financial expenses	-0.7	-1.5
Dividends paid to:		
- Shareholders of Sartorius Stedim Biotech SA	0.0	0.0
- Non-controlling Interest	0.0	0.0
Gross cash flows from financing activities	-0.6	-1.5
Loans and borrowings repaid (-) raised (+)	-0.6	18.8
Net cash flow from financing activities	-1.2	17.4
Net increase decrease in cash and cash equivalents	4.1	20.0
Cash and cash equivalents at the beginning of the period	18.5	35.6
Net effect of currency translation on cash and cash equivalents	2.2	-0.1
Cash and cash equivalents at the end of the period	24.9	55.5